Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Heart Failure|August 3, 2026
Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCMShepard D Weiner, Lusha W Liang, Ahmad Masri, et al.
Circulation|September 17, 2019
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF TrialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
JACC. Heart Failure|August 17, 2024
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure: Results of the PROACTIVE-HF TrialJason L Guichard, Eric L Bonno, Michael E Nassif, et al.
Nature Medicine|March 1, 2022
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A Voors, Christiane E Angermann, John R Teerlink, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|January 6, 2026
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyMichael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, et al.
Pageof 9